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Clhcai outcome, early and late LV function and 
infarct size (IS) were estimated in 180 pts randomly allocated 
effective 6n clinical Outcome, patency rate, infart size 
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ACEBUTOLOL ANB THE SEC0 ARV PRRVENTION IN HIC 
POST-MI PATIENTS (APSI) 
by J.P. Boiseell, Lyon, 
cabo (PL) controlled tri 
c acebutolol, 200 mg b.i 
(BB: with mild intrinsic aympathomimetic 
tiv-ity (ISA), in the prevention of late death in RiBb 
sk post myocardial infarction (MI) patients. APSI was 
planned because : l/ patienta with death race greater 
than 20% have not been enrolled in significant numbers 
in previous trials ; 2/ in such high risk patients it 
remained to be proven that BBe h 
Patients with an expected averag 
be selected based on clinical cr 
the 2nd interim analysis the PL group one year mortality 
was much lower than expected (12%). The Ethical Board 
recommended to stop the trial. 309 patients have been 
allocated to PL, 298 to AC. The average delay between 
onset of symptoms and inclusion was 10.5 days. The 
average follow-up was 318.5 days after inclusion. About 
the same number of patients were discontinued from study 
treatment in both group@. 
the analysis. There were 
highest ever observed wit 
of death, including heart failure, were less frequent in 
the AC group. The total mortality reduction wa 
apparently correlated with the class of risk. 
the objective was not achieved, APSI patients were at 
higher risk than the average of the 9 previous trials 
with BB (12% instead 7.2%). APSI shows l/ moderately 
severe post-MI patients can benefit from a beta-blocking 
treatment ; 21 a BB with mild ISA can be effective. 
